Johnson & Johnson Submits Caplyta Application for Bipolar Mania
Johnson & Johnson said it submitted a supplemental new drug application for Caplyta in bipolar mania.
Johnson & Johnson said it submitted a supplemental new drug application for Caplyta in bipolar mania.